This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine

While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.The Johnson & Johnson Analyst: Analyst Asad Haider upgraded the rating from Neutral to Buy, while raising the price target from $157 to$172.The Johnson & Johnson Thesis: While the Innovative Medicine business contributes around 65% of the company's revenues, it accounts for 83% of profits, which is why it is " ...